Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$391.00K$391.00K−23.9% vs Q1 2020 Net Income-$1.42M-$1.42MN/M vs Q1 2020 EPS Diluted-$0.01-$0.01N/M vs Q1 2020 Gross Profit$279,000−33.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$7,424,000N/M Free Cash Flowderived-$7,435,000N/M Margins · derivedGross margin71.4%−10.4 pt vs Q1 2020
Operating margin-1803.1%−356.0 pt vs Q1 2020
Net margin-362.1%+1271.9 pt vs Q1 2020
ended Mar 31, 2021 · filed May 13, 2021 · 43 d after period end